CSIMarket
 


Amneal Pharmaceuticals Inc   (AMRX)
Other Ticker:  
 
 

AMRX's Net Income Growth by Quarter and Year

Amneal Pharmaceuticals Inc 's Net Income results by quarter and year




AMRX Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -93.34 -5.86 -20.46 -22.03
III Quarter September 25.03 -2.39 -6.09 -23.94
II Quarter June 29.68 -240.08 32.18 121.52
I Quarter March -10.09 -6.46 14.55 -64.90
FY   -48.72 -254.79 20.18 10.65



AMRX Net Income fourth quarter 2023 Y/Y Growth Comment
Amneal Pharmaceuticals Inc in the fourth quarter 2023 recorded net loss of $ -93.34 millions.

Among companies who have reported fourth quarter 2023 results in the Major Pharmaceutical Preparations industry only one Company has achieved higher year on year Net Income results in the fourth quarter 2023. While Amneal Pharmaceuticals Inc ' s Net Income no change of % ranks overall at the positon no. 74 in the fourth quarter 2023.




AMRX Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - -73.52 % -
I Quarter March - - - -
FY   - - 89.48 % -

Financial Statements
Amneal Pharmaceuticals Inc 's fourth quarter 2023 Net Income $ -93.34 millions AMRX's Income Statement
Amneal Pharmaceuticals Inc 's fourth quarter 2022 Net Income $ -5.86 millions Quarterly AMRX's Income Statement
New: More AMRX's historic Net Income Growth >>


AMRX Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September -15.67 % - - -
II Quarter June - - 121.17 % -
I Quarter March - - - -
FY (Year on Year)   - - 89.48 % -




Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #5
Overall #74

Net Income Y/Y Growth Statistics
High Average Low
89.62 % -7945.81 % -36805.91 %
(Dec 31 2021)   (Jun 30 2022)
Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #5
Overall #74
Net Income Y/Y Growth Statistics
High Average Low
89.62 % -7945.81 % -36805.91 %
(Dec 31 2021)   (Jun 30 2022)

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Amneal Pharmaceuticals Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AMRX's IV. Quarter Q/Q Net Income Comment
Recent accomplishment of -93.34 millions by Amneal Pharmaceuticals Inc look even less good compare to the 25.03 millions in the third quarter.

Within Major Pharmaceutical Preparations industry Amneal Pharmaceuticals Inc achieved highest sequential Net Income growth. While Amneal Pharmaceuticals Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AMRX's IV. Quarter Q/Q Net Income Comment
Current accomplishment of -93.34 millions by Amneal Pharmaceuticals Inc come out even worse considering the 25.03 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Amneal Pharmaceuticals Inc achieved highest sequential Net Income growth. While Amneal Pharmaceuticals Inc 's Net Income growth quarter on quarter, overall rank is .


Amneal Pharmaceuticals Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Income 12 Months Ending $ -48.72 $ 38.76 $ 11.34 $ -258.42 $ -254.79
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - 241.8 % - - -
Seq. Net Income Growth (TTM) Overall Ranking # 74 # 121 # 0 # 715 # 0




Cumulative Net Income growth Comment


Amneal Pharmaceuticals Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
89.62 %
-7945.81 %
-36805.91 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 5
S&P 500 # 74
Cumulative Net Income growth Comment


Amneal Pharmaceuticals Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
89.62 %
-7945.81 %
-36805.91 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 5
S&P 500 # 74




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
AMRX's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for AMRX's Competitors
Net Income Growth for Amneal Pharmaceuticals Inc 's Suppliers
Net Income Growth for AMRX's Customers

You may also want to know
AMRX's Annual Growth Rates AMRX's Profitability Ratios AMRX's Asset Turnover Ratio AMRX's Dividend Growth
AMRX's Roe AMRX's Valuation Ratios AMRX's Financial Strength Ratios AMRX's Dividend Payout Ratio
AMRX's Roa AMRX's Inventory Turnover Ratio AMRX's Growth Rates AMRX's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 31 2023
Penumbra Inc 1,298.45%$ 1,298.452 millions
Axonics Inc 888.57%$ 888.571 millions
Livanova Plc883.68%$ 883.685 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com